Alexander J. Denner, the company's largest shareholder, purchased 7,000 shares in a deal that took place on Monday 5th June. The shares were purchased at an average of $13.04 a share for a total of $91,280.00. The insider owns now 7,207,000 shares worth $93,979 280. The SEC requires large shareholders who own 10% or greater of the shares in a company to report their transactions.
Innoviva Stock Performance
Trading at midday on Wednesday saw the stock rise $0.34 to $13.40. The company traded 578,072 more shares than its average of 697.640. The company's current ratio is 7.77. Its quick ratio is 6.47. And its debt-to equity ratio is 0.79. Innoviva, Inc.'s 12-month low is $10.64, and its 12-month high is $15.67. The fifty-day moving standard is $12.25, and the 200-day is $12.43. Recently, hedge funds bought and sold the stock. Quadrant Capital Group, LLC increased its holdings in Innoviva in the third quarter by 2,417.4%. Quadrant Capital group LLC owns 2,165 of the biotechnology firm's shares worth $25,000, after buying an additional 2,079 in the last quarter. CWM LLC increased its holdings in Innoviva in the first quarter by 275.4%. CWM LLC owns 2,620 of the biotechnology firm's stock, worth $29,000, after buying an additional 1,922 in the last quarter. Captrust Financial Advisors increased its stake in Innoviva in the first quarter by 362.2%. Captrust Financial Advisors owns 2,699 of the biotechnology firm's stock, worth $52,000, after buying an additional 2,115 in the last quarter. Signaturefd LLC increased its holdings in Innoviva shares by 970.2% over the first quarter. Signaturefd LLC owns now 2,729 of the biotechnology stock worth $31,000, after purchasing an additional 2,474 in the last quarter. Point72 Hong Kong Ltd also purchased shares of Innoviva in the first quarter, valued at $76,000.
Analyst Ratings Changes
INVA was the subject of recent analyst reports. Morgan Stanley reduced their price target on shares of Innoviva to $10 from $13.00 in a report published on Friday, 3rd March. They also set an "underweight" rating for the stock. TheStreet downgraded Innoviva shares from a "b-" rating to a "c+" rating in a Thursday, February 23, 2018 report. EF Hutton Acquisition Co. Innoviva was upgraded from a "hold" rating to a "buy" rating in a report published on Thursday, May 11. Innoviva's target price was reduced by The Goldman Sachs Group from $15 to $13, and the company's rating was reaffirmed as 'neutral.' This happened in a report published on Friday, 3rd March. Two analysts have given the stock a buy recommendation, while one analyst has assigned a hold recommendation. According to MarketBeat data, the average rating for the company is 'Hold' with an average price target of $15.17.
Innoviva, Inc. is involved in the development, marketing, and financial management biopharmaceuticals. Innoviva's portfolio includes Relvar Breo Ellipta which is a combination medicine consisting once daily of a beta2 agonist (vilanterol) and an inhaled steroid (fluticasone fuoate), and Anoro Ellipta which is a medicine that combines a muscarinic long-acting antagonist, umeclidinium, bromide.
MarketBeat.com offers a FREE daily email newsletter